# ESMO PRECEPTORSHIP PROGRAMME GASTRIC CANCER

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

## Madrid, Spain 5-6 September 2025

**CO-CHAIRS** 

Tania Fleitas, Spain Hanneke van Laarhoven, The Netherlands **SPEAKERS** 

Sara De Dosso, Switzerland Sarah Derks, The Netherlands Mário Dinis-Ribeiro, Portugal Maria Hawkins, United Kingdom Carolina Martinez Ciarpaglini, Spain Magnus Nilsson, Sweden Guillaume Piessen, France

#### LEARNING OBJECTIVES

- To learn about the fundamentals of epidemiology, aetiology, pathogenesis, molecular events and immune biology of gastric and esophago-gastric junction (EGJ) cancer
- To understand the essentials in the diagnosis and multidisciplinary treatment of gastric and EGJ cancer
- To learn about advances in the treatment and novel targets in gastric and EGJ cancer
- To learn about supportive care for gastric and EGJ cancer management

### Friday, 5 September 2025

09:00-09:10 10'	Opening and welcome	
10'	Welcome and introduction	Tania Fleitas, ES Hanneke van Laarhoven, NL

09:10-10:55 105'	SESSION 1 Pathology and diagnosis of gastric cancer	Chair:
20'	Gastric cancer as a global health problem	Tania Fleitas, ES
5'	Q&A	All
25'	Pathology and classification of gastric cancer	Carolina Martinez Ciarpaglini, ES
5'	Q&A	All
25'	Tumour microenvironment of gastric and GEJ cancer	Sarah Derks, NL
5'	Q&A	All
20'	Challenge your expertise	Tania Fleitas, ES and Hanneke van Laarhoven, NL

10:55-11:25	Coffee break	
11:25-12:55 90'	SESSION 2 – Part I Early and locally advanced gastric and EGJ cancer	Chair:
25'	Endoscopic diagnosis, staging and treatment of early gastric cancer	Mário Dinis-Ribeiro, PT
5'	Q&A	All
25'	Surgery for gastric and EGJ cancer	Guillaume Piessen, FR
5'	Q&A	All
25'	Neoadjuvant and perioperative treatment for locally advanced gastric cancer	Sara De Dosso, CH
5'	Q&A	All
12:55-13:55	Lunch	
13:55-15:45 110'	SESSION 2 – Part II Early and locally advanced gastric and EGJ cancer	Chair:
25'	When to include radiation in the curative treatment of gastric and EGJ cancer in 2025	Maria Hawkins, UK
5'	Q&A	All
60'	Participants clinical case discussion (4x15')	Faculty
20'	Challenge your expertise	Tania Fleitas, ES and Hanneke van Laarhoven, NL
15:45-16:15	Coffee break	
16:15-17:45 90'	SESSION 3 Supportive care	Chair:
25'	Role of exercise and nutrition in gastric and EGJ cancer	Hanneke van Laarhoven, NL
5'	Q&A	All
25'	Endoscopic options for treatment of gastric outlet and nutritional difficulties	Mário Dinis-Ribeiro, PT
5'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty

# Saturday, 6 September 2025

Dinner

20:30

09:00-10:30 90'	SESSION 4 – Part I Advanced disease	Chair:
25'	Sequential chemotherapy (doublet, triplet, elderly patients, sequences, anti-angiogenic therapy, oral chemotherapy)	Tania Fleitas, ES
5'	A&D	All
25'	Biologically targeted treatment (HER2, Claudin 18.2, FGFR2, and beyond)	Sara De Dosso, CH

5'	Q&A	All
25'	Immunotherapy in gastric and EGJ cancer	Sarah Derks, NL
5'	Q&A	All

11:00-13:10 130'	SESSION 4 – Part II Advanced disease	Chair:
20'	Treatment of oligometastatic gastroesophageal cancer	Hanneke van Laarhoven, NL
5'	Q&A	All
20'	Peritoneal gastric cancer management	Magnus Nilsson, SE
5'	Q&A	All
60'	Participants clinical case discussion (4x15')	Faculty
20'	Challenge your expertise	Tania Fleitas, ES and Hanneke van Laarhoven, NL
10 10 10 15		Tonio Floites FC

13:10-13:15 5'	Future outlook, conclusion and farewell	Tania Fleitas, ES Hanneke van Laarhoven, NL
13:15-14:15	Lunch	

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion